AIM ImmunoTech is trading 5.5% down at $0.21 in pre-market as broader risk-off conditions, including weaker U.S. futures and rate concerns, appear to be the primary context after no clear company-specific catalyst emerged overnight.
- The latest official company release, dated September 9, 2026, highlighted Ampligen’s pancreatic-cancer clinical progress rather than negative news.
- Recent debt-for-equity exchanges converted approximately $1.22 million of debt into shares, potentially raising dilution concerns, though available coverage does not directly link the announcement to the September 14 move.